KRAS / RAS 靶向 — 从平台化到 Ph3 验证
现场把这件事从「G12C 单药还能撑多久」改写成「谁先把 1L 胰腺癌做成标准治疗」。daraxonrasib 的 III 期是目前唯一的 RAS 抑制剂总生存阳性；G12D 的 zoldonrasib 与 VS-7375 还在 I 期，数字好看但样本小，不能直接互比。
⭐️ Excellent #AACR26 abstract breakdown of 🔑 abstracts for #CommunityOncology by the @OncBrothers
⭐️#CM77T
⭐️#TRUST
⭐️#RMC-9805-001
⭐️#LB407
⭐️#LB337
#Onctwitter #MedTwitter #MedX @AACR #gism #lcsm #FOAMed #MedEd #Oncology
#KRAS #CancerResearch #Cancer #NSCLC
Heat 13 · 9 likes · 0 replies · 4 reposts
Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal
Read the abstract →Eileen M. O'Reilly, Brian Wolpin, Shubham Pant, Joel Randolph Hecht, Jennifer Valerin, Dae Won Kim, Nilofer Azad, Kyaw Aung, Lin Tao, Sumit Kar, Hina Patel, Rashmi Vora, Aparna Hegde, Alexander Spira, Alexander Starodub, Benjamin Herzberg, Ignacio Garrido-Laguna
Read the abstract →Source: AACR 2026 现场信号 · x.com